Discussion club on nephrology «Modern view on the therapy of secondary hyperparathyroidism in hemodialysis patients»


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

5 ноября 2021 г. при поддержке компании «Амджен» состоялась прямая интернет-трансляция дискуссионного клуба по нефрологии «Современный взгляд на терапию вторичного гиперпаратиреоза у пациентов на гемодиализе».

Full Text

Restricted Access

About the authors

- -

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 200; 64(3):1022-1026 2017;7(1):1-59.
  2. Block G.A., Kilpatrick R.D., Lowe K.A. et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 2013;8(12):2132-40. Doi: 10.2215/ CJN.04260413.
  3. Floege J., Kim J., Ireland E. et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26:1948-55.
  4. Chertow G.M., Block G.A., Correa-Rotter R. et al. Effect of cinacalcet on car-. diovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-94.
  5. Chertow G.M., Block G.A., Correa-Rotter R. et al. Effect of cinacalcet on car-. diovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-94.(Suppl 1-54).
  6. Schmidt I.M. et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study.Clinical Kidney Journal 2019, 12(5): 663-72.
  7. Ghimire S et al. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLOS ONE 2015. D0I:10.1371/journal.pone.01441195.
  8. Tentori E, Wang M., Bieber B.A. et al. Recent changes in therapeuticapproaches and association with outcomes among patients withsecondary hyperparathyroidism on chronic hemodialysis: the DOPPSstudy. Clin J Am Soc Nephrol 2015; 10: 98-109.
  9. Karaboyas А. et al., Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients, AJKD 2021, doi: 10.1053/j.ajkd.2021.05.020.
  10. Neri L., Martini A., Andreucci V.E., Gallieni M., Rey L.A., Brancaccio D. MigliorDialisi Study Group. Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol. 2011;34(1):71-6. doi: 10.1159/000328391. Epub 2011 Jun 14. PMID: 21677429.
  11. Arenas M.D., Rodelo-Haad C., Pendon-Ruiz de Mier M.V., Rodriguez M. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent oral calcimimetics. Clin. Kidney J. 2020. doi: 10.1093/ckj/sfaa005.
  12. Campillejo R., et al. Effectiveness and safety of etelcalcetide in the long term in clinical practice in hemodialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_3, June 2020, gfaa142.P1426.
  13. Yokoyama K. et al. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan. Clinical and Experimental Nephrology 2020, doi: 10.1007/s10157-020-01936-2.
  14. Bushinsky D.A., Chertow G.M., Cheng S., et al. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2019:1-10. doi: 10.1093/ndt/gfz039
  15. Сunningham J. et al. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Reports 2019, 4:987-94.
  16. Block G.A., Bushinsky D.A., Cheng S., et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156-64.
  17. Nduka C., et al. ASN KidneyWeek 2021; Poster Abstract: PO0547
  18. Dorr K., Kammer M., Reindl-Schwaighofer R., Lorenz M., Prikoszovich T., Marculescu R., Beitzke D., Wielandner A., Erben R.G., Oberbauer R. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. Circ Res. 2021 May 28;128(11):1616-25.
  19. Adapted from Isakova T et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79,:1370-78.
  20. Makoto Kuro-o, Klotho and calciprotein particles as therapeutic targets against accelerated ageing. Clin Sci (Lond). 2021 Aug;135(15): 915-27.
  21. Cristian Rodelo-Haad, et al. FGF23, Biomarker or Target? Toxins (Basel). 2019 Mar; 1(3):175.
  22. Jair Munoz Mendoza, et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 2017 Mar; 91(3): 711-19.
  23. Mehta R, et al. Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. Clin J Am Soc Nephrol. 2017;12:1795-803.
  24. Evangelos Memmos, et al. Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis. BMC Nephrol. 2019; 20: 217.
  25. QiFeng Liu, et al. Correlation Between Soluble Klotho and Vascular Calcification in Chronic Kidney Disease: A Meta-Analysis and Systematic Review. Front Physiol. 2021;12:711904.
  26. Moe S.M. et al. Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015 Jun;26(6):1466-75.
  27. Behets G.J. et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int. 2015 Apr;87(4):846-56.
  28. Raggi P. et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1327-39.
  29. Xipell M. et al. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. Blood Purif. 2019; 48(2):106-14.
  30. Itano Y. et al. A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). Kidney Int Rep. 2020 Sep 18;5(12):2168-77.
  31. Palmer S.C. et al. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis. 2020 Sep;76(3):321-330.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies